Comparative Pharmacology
Head-to-head clinical analysis: UTIMOX versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UTIMOX versus V CILLIN.
UTIMOX vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
For UTIMOX (amoxicillin/clavulanate), typical adult dose is 875 mg/125 mg orally every 12 hours or 500 mg/125 mg orally every 8 hours, depending on infection severity.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function; prolonged to 3-5 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 8-12 hours in severe impairment (CrCl <30 mL/min).
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Primarily renal (85-90% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal excretion accounts for less than 10%.
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic